Nuvation Bio Increases Convertible Notes Offering to $250 Million
Nuvation Bio "announced the pricing of its underwritten offering of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due in 2032. The aggregate principal amount of the Offering was increased from the previously announced offering size of $200.0 million. The sale of the Notes to the underwriters is expected to close on June 30, 2026, subject to customary closing conditions. The conversion rate will initially be 127.4941 shares of Class A common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $7.84 per share of Class A common stock, which represents a conversion premium of approximately 35.0% to the last reported sale price of the Class A common stock on the New York Stock Exchange on June 25, 2026)."
